Pharmaceuticals
Seegene Earns Improved ESG Rating from the Korea Institute of Corporate Governance and Sustainability
Company attributes B+ rating to progress related to its Human Rights Management Declaration, eco-friendly shipping box and the establishment of an internal ESG Committee SEOUL, South Korea, Nov. 10, 2023 /PRNewswire/ -- Seegene Inc. (KQ096530), a leading South Korean company providing a total so...
2023-11-10 20:00
4529
Shaping Global Policy: IFPA's Psoriatic Disease Response Index in the Western Pacific
STOCKHOLM, Nov. 10, 2023 /PRNewswire/ -- Psoriatic disease, recognized as a serious noncommunicable disease by the World Health Organization (WHO), impacts millions worldwide. A pioneering advocacy tool, the Psoriatic Disease Response Index, has emerged to facilitate a vital policy discussion, dr...
2023-11-10 19:18
4522
H2U Secures Strategic Investment from InnoTherapy as Recognition from Seoul Clinical Laboratories (SCL)
H2U platform enters the South Korean healthcare sector, driving AI-powered data analytics to expand their digital health offerings TAIPEI, Nov. 10, 2023 /PRNewswire/ -- H2U, Taiwan's premier digital health brand, proudly announced another successful round of funding this year after receiving rec...
2023-11-10 17:48
3468
Noah Launches "Play The Full Game" Campaign with Singaporean Football Legend Fandi Ahmad as Brand Ambassador
SINGAPORE, Nov. 9, 2023 /PRNewswire/ -- Noah, the telehealth platform tailored for men and created by Ordinary Folk, is pleased to announce the launch of its "Play The Full Game" campaign and the appointment ofFandi Ahmad as Noah's brand ambassador. The campaign aims to empower men to have the co...
2023-11-09 14:31
2847
West Pharmaceutical Services Appoints Nilesh Shah as Vice President and General Manager of Emerging Markets
SINGAPORE, Nov. 9, 2023 /PRNewswire/ -- West Pharmaceutical Services, Inc.
2023-11-09 12:58
10353
DiscGenics Announces Research Collaboration with the U.S. Department of Veterans Affairs for Tissue-Engineered Discs with Discogenic Cells
Feasibility Project Awarded VA Technology Transfer Program BRAVE Funding SALT LAKE CITY, Nov. 9, 2023 /PRNewswire/ -- DiscGenics, Inc., a privately held, late-stage clinical, biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function...
2023-11-09 08:15
2638
Dr. Jinzi J. Wu Presents at the 10th International Workshop on HBV Cure 2023
HANGZHOU and SHAOXING, China, Nov. 9, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that Dr.Jinzi J. Wu, Founder, Chairman and CEO of Ascletis was invited to attend and have a presentation at the 10th International Workshop on HBV Cure 2023 held atBoston, Unit...
2023-11-09 08:10
5610
Telix to Present at Jefferies London Healthcare Conference 2023
MELBOURNE, Australia, Nov. 9, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises that DrChristian Behrenbruch, Managing Director and Group CEO, will be presenting at the Jefferies London Healthcare Conference 2023. The presentation will take place o...
2023-11-09 04:51
2359
Allgenesis Announces Encouraging Preliminary Safety and Efficacy Data from the AG-73305 Phase 2a Trial for the Treatment of Diabetic Macular Edema at American Academy of Ophthalmology
TAIPEI, Nov. 8, 2023 /PRNewswire/ -- * AG-73305 was found to be safe and tolerable with no severe adverse effects (SAEs) after a single intravitreal injection of doses of 0.5, 1, 2, and 4 mg in DME patients. * Data combining all 4 cohorts showed mean improvement in Best Corrected Visual Acc...
2023-11-08 23:23
2281
Telix and Wiik Pharma Sign Distribution Agreement for Illuccix® in the Nordic Region
MELBOURNE, Australia, Nov. 8, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has signed an exclusive agreement withDenmark-based WIIK Pharma ApS (Wiik Pharma) for the distribution of Telix's investigational prostate cancer imaging agent, Illuc...
2023-11-08 13:00
2491
Docquity Expands Digitized Patient Access Programs To Enhance Healthcare Outcomes in Thailand
* After a successful pilot in the Philippines, five DocquityCare Patient Access Programs (PAPs)have been launched in Thailand * DocquityCare PAP will support more than 100 hospitals and 250 healthcare professionals (HCPs) to improve patient care for those with cancer and other life-threatenin...
2023-11-08 10:00
3451
Antengene to Host 2023 R&D Day and Discuss Key Data with KOLs
* During the event, Antengene will review promising data of its R&D pipeline, includingATG-031 (anti-CD24 monoclonal antibody), ATG-101 (PD-L1/4-1BB bispecific antibody), ATG-022 (Claudin 18.2 antibody-drug conjugate), ATG-037 (CD73 inhibitor), and ATG-008 (dual mTORC1/2 inhibitor). * The vir...
2023-11-08 08:30
2503
Menarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to Develop and Commercialize ORSERDU® (Elacestrant) in China to Address Advanced or Metastatic Breast Cancer
* ORSERDU is the first treatment specifically approved for patients with ER+, HER2- advanced or metastatic breast cancer tumors that harbor ESR1 mutations, representing the first innovation in endocrine therapy in nearly 20 years. * ESR1 mutations are present in up to 40% of ER+, HER2- advance...
2023-11-08 02:01
2468
Turn Biotechnologies First to Deliver mRNA into the Dermis Using Proprietary LNPs, With No Distribution to Other Organs
* Company's eTurna™ delivery platform ensures unprecedented precision, safety * In-vivo biodistribution of mRNA into dermal cells, tissues shows high transfection efficiency, gene expression * Data presented at ASDS Annual Meeting MOUNTAIN VIEW, Calif., Nov. 7, 2023 /PRNewswire/ -- Turn Biot...
2023-11-07 21:30
3635
KN026 was Granted Breakthrough Therapy Designation by CDE
SUZHOU, China, Nov. 7, 2023 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK) jointly announced, that the Center for Drug Evaluation (CDE) ofChina's National Medical Products Administration (NMPA) granted a Breakthrough Therapy d...
2023-11-07 08:51
2379
Unveiling the hidden struggles: Survey reveals worrying knowledge gap and emotional toll of infertility amidst record-low birth rates in Asia
* A survey conducted in seven Asian markets, including Indonesia, revealed that respondents, on average, spent 6.8 years on their fertility journey, with 3.6 years dedicated to trying to conceive naturally.1,2 * In Indonesia, Japan, Korea, Singapore, and Vietnam, at least 70 percent of respon...
2023-11-07 08:15
1508
Unveiling the hidden struggles: Survey reveals worrying knowledge gap and emotional toll of infertility amidst record-low birth rates in Asia
* A survey conducted in seven Asian markets, including India, revealed that respondents, on average, spent 6.8 years on their fertility journey, with 3.6 years dedicated to trying to conceive naturally.1,2 * In Indonesia, Japan, Korea, Singapore, and Vietnam, at least 70 percent of respondent...
2023-11-07 08:15
1367
Unveiling the hidden struggles: Survey reveals worrying knowledge gap and emotional toll of infertility amidst record-low birth rates in Asia
* A survey conducted in seven Asian markets, including Vietnam, revealed that respondents, on average, spent 6.8 years on their fertility journey, with 3.6 years dedicated to trying to conceive naturally.1,2 * In Indonesia, Japan, Korea, Singapore, and Vietnam, at least 70 percent of responde...
2023-11-07 08:15
1802
Unveiling the hidden struggles: Survey reveals worrying knowledge gap and emotional toll of infertility amidst record-low birth rates in Asia
* A survey conducted in seven Asian markets, including Taiwan, revealed that respondents, on average, spent 6.8 years on their fertility journey, with 3.6 years dedicated to trying to conceive naturally.1,2 * In Indonesia, Japan, Korea, Singapore, and Vietnam, at least 70 percent of responden...
2023-11-07 08:15
1572
Phase I Study Results for Qilu Pharmaceutical's Iparomlimab (QL1604) Now Published
JINAN, China, Nov. 6, 2023 /PRNewswire/ -- Recently, the results of the Phase I study for iparomlimab (R&D code: QL1604), developed by Qilu Pharmaceutical Co., Ltd. were published online in the academic journalFrontiers in Immunology (2022 Impact Factor: 7.3). The title of the paper is "A first-i...
2023-11-06 18:54
2106
Week's Top Stories
Most Reposted
Agoda Launches Free Global eSIMs for VIP Diamond Members
[Picked up by 322 media titles]
2026-02-10 14:00
DBS is First Bank in Asia Pacific to Pilot Visa Intelligent Commerce for Everyday Payments
[Picked up by 320 media titles]
2026-02-16 10:00
Ascentium Acquires Clara, Expanding into the Abu Dhabi Global Market (ADGM) and Strengthening its Middle East Presence
[Picked up by 310 media titles]
2026-02-12 14:00
Blackpanda Japan Announces Strategic Partnership with SoftBank to Strengthen Cyber Incident Response in Japan
[Picked up by 298 media titles]
2026-02-10 13:31Carro unveils quirky generative AI ad campaign highlighting its 'Surprisingly Short' AI-enabled car-selling process
[Picked up by 296 media titles]
2026-02-11 11:00
Most Read
Agoda Launches Free Global eSIMs for VIP Diamond Members
2026-02-10 14:00
6808
Datasea Reports Second Fiscal Quarter 2026 Results
2026-02-12 22:20
6650
eufy Raises the Bar for Home Cleaning with Omni C28, Delivering One-Pass-Clean Performance with HydroJet™ Self-Clean Roller Mop
2026-02-14 10:00
6586
NYSE Content Update: Forgent Power Solutions, Post IPO, to Ring Opening Bell
2026-02-12 21:56
5733
